Skip to content

Diagnosis and Intervention of Complicated Twin Diseases

Diagnosis and Intervention of Complicated Twin Diseases in China

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03650985
Enrollment
100
Registered
2018-08-29
Start date
2018-08-31
Completion date
2022-08-31
Last updated
2018-09-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Twin Diseases

Brief summary

Fetal medicine in China is still a new, young discipline, and the development is very rapid. After nearly 10 years of development, the clinical diagnosis and treatment guidelines of some complicated twin diseases has been established , but they are still needed to be improved. Through this study, the investigators expect to achieve better prediction indicators and early intrauterine precise diagnosis of complicated twin diseases. Also, better procedures of implementing effective intrauterine intervention and assessing the safety and effectiveness of intrauterine intervention are anticipated to be established.

Detailed description

A better guideline for complicated twin diseases are anticipated to be established in China. Molecular genetics and imaging technology are applied to evaluate the outcome and prognosis of intrauterine intervention for complex twin diseases. 3D printing technology is used to assist the preoperative evaluation of fetal intrauterine intervention. Better fetal intrauterine intervention technique and prognosis evaluation are expected to be established.

Interventions

PROCEDUREFetoscope technique

Intrauterine intervention with fetoscope technique will be applied to treat complex twin diseases with intention to improve the prognosis of patients.

Sponsors

Shengjing Hospital
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

Pregnancy women with complicated twin diseases, who are able to withstand risks of intrauterine treatments and informed consent.

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 50 Years
Healthy volunteers
Yes

Inclusion criteria

* Pregnancy women with complicated twin diseases who are able to withstand intrauterine treatment and consent informed.

Exclusion criteria

* Pregnancy women who refuse intrauterine treatment.

Design outcomes

Primary

MeasureTime frameDescription
Gene expression of fetusesAt 20 week of gestational ageDNA methylation, histone acetylation etc. assessed by analyses of fetal blood and amniotic fluid.
Change of volume of amniotic fluid in MilliliterAt every two week from the sixteenth week of gestational age to delivery of babiesMeasured by doctors of sonography
Change of umbilical artery blood flowAt every two week from the sixteenth week of gestational age to delivery of babiesMeasured by doctors of sonography

Secondary

MeasureTime frameDescription
Neurodevelopment at early childhoodAt age of 1 year oldIncluding adaptive, gross motor, fine motor, language, and social function; assessed using Gesell Developmental Schedules.

Countries

China

Contacts

Primary ContactCaixia Liu
liucx1716@163.com86-18902451716
Backup ContactShaojiang Liu
liushaojiang1995@qq.com86-18002454803

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026